Lucid Diagnostics’ (LUCD) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Lucid Diagnostics (NASDAQ:LUCDFree Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $3.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Lucid Diagnostics’ FY2024 earnings at ($1.06) EPS.

Separately, Needham & Company LLC reissued a buy rating and set a $2.50 price target on shares of Lucid Diagnostics in a report on Monday, May 13th.

Check Out Our Latest Report on LUCD

Lucid Diagnostics Stock Up 1.7 %

LUCD stock opened at $0.91 on Wednesday. The company has a fifty day moving average price of $0.93 and a two-hundred day moving average price of $1.21. Lucid Diagnostics has a one year low of $0.63 and a one year high of $1.85.

Lucid Diagnostics (NASDAQ:LUCDGet Free Report) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($0.26) EPS for the quarter. The company had revenue of $1.04 million during the quarter. Lucid Diagnostics had a negative net margin of 1,576.60% and a negative return on equity of 901.79%. During the same quarter in the prior year, the business posted ($0.22) EPS. Research analysts forecast that Lucid Diagnostics will post -1.06 EPS for the current year.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics Inc, a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.

Read More

Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with's FREE daily email newsletter.